文献速递血管炎

巨细胞动脉炎中持续无药缓解

Sustained drug-free remission in giant cell arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该西班牙多中心回顾性研究纳入872例巨细胞动脉炎患者,随访至少2年,21.2%达到持续无药缓解(SDFR),2、3、4年累积率分别为6.3%、20.5%、25.3%。复发和诊断时需静脉甲泼尼龙冲击与SDFR可能性降低显著相关,达到SDFR后复发率低。

要点

  • 872例巨细胞动脉炎患者中21.2%达到持续无药缓解,2、3、4年累积率分别为6.3%、20.5%、25.3%。
  • 复发(IRR 0.492,P < 0.001)和诊断时需静脉甲泼尼龙冲击(IRR 0.575,P = 0.003)与达到SDFR可能性降低显著相关。
  • 达到SDFR后仅5例(2.7%)复发,中位复发时间为达到SDFR后19个月(四分位距14-35个月)。

主要发现

  • 47%的患者接受了托珠单抗和/或免疫抑制剂(主要为甲氨蝶呤)的联合治疗。
  • 21.2%(185/872)的患者达到持续无药缓解。
  • 达到SDFR的患者在2、3、4年的累积率分别为6.3%、20.5%和25.3%。
  • 达到SDFR的患者较未达到者能更快将泼尼松剂量减至10 mg/天(P = 0.090)和5 mg/天(P = 0.002)。
  • 达到SDFR的患者复发更少见(P = 0.006)。

关键数值与推荐

  • 持续无药缓解定义为停用治疗后至少12个月无典型体征、症状或其他活动性巨细胞动脉炎特征。
  • 复发与达到SDFR可能性降低显著相关(IRR 0.492,P < 0.001)。
  • 诊断时需静脉甲泼尼龙冲击与达到SDFR可能性降低显著相关(IRR 0.575,P = 0.003)。
  • 仅5例(2.7%)出现复发,中位复发时间为达到SDFR后19个月(四分位距25th-75th:14-35个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to evaluate the frequency and timing of sustained drug-free remission (SDFR) in patients with GCA and to identify potential predictive factors of this outcome. METHODS: A retrospective review of all patients included in the large Spanish multicentre registry for GCA (ARTESER) with at least 2 years of follow-up was undertaken. SDFR was defined as the absence of typical signs, symptoms, or other features of active GCA for ≥12 months after discontinuation of treatment. RESULTS: We included 872 patients. Forty-seven percent had received concomitant treatment with tocilizumab and/or immunosuppressants, mainly MTX. SDFR was achieved in 21.2% (185/872) of the patients. The cumulative rates of patients achieving SDFR at 2, 3 and 4 years were 6.3%, 20.5% and 25.3%, respectively. Patients who achieved SDFR could reduce their prednisone dosage to 10 mg/day (P = 0.090) and 5 mg/day (P = 0.002) more quickly than those who did not. Relapses were less frequent in patients with SDFR (P = 0.006). The presence of relapses [incident rate ratio (IRR): 0.492, P < 0.001] and the need for i.v. methylprednisolone boluses at diagnosis (IRR: 0.575, P = 0.003) were significantly associated with a decreased likelihood of achieving SDFR. Only 5 patients (2.7%) experienced a recurrence, with a median onset of 19 months after achieving SDFR (interquartile range 25th-75th: 14-35 months). CONCLUSION: Within 3-4 years of diagnosis, only one-quarter of patients with GCA successfully reached the SDFR. Once the SDFR was achieved, the likelihood of experiencing recurrence was low. Relapses and the need for glucocorticoid boluses appear to have been predictors of the need for long-term glucocorticoids.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Narváez J, Domínguez M, Galíndez E, et al. Sustained drug-free remission in giant cell arteritis. Rheumatology (Oxford). 2025. PMID: 39589919. doi:10.1093/rheumatology/keae644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。